Rising Expectations for New Pulmonary Disease Drugs... Nasdaq Biotech Surges Over 5 Trillion Won in One Day

U.S. biotech company Insmed Inc. (NASDAQ: INSM) rallied 13.39% on the Nasdaq on the 12th, closing at $117.80. Trading volume reached about 6 million shares, and the company’s market capitalization swelled to roughly $25.5 billion (approximately ₩35 trillion), adding about $4 billion (₩5.5 trillion) in a single day.

That same day, Bank of America reaffirmed its “Buy” rating on Insmed with a $214 price target, citing strong launch momentum for its new drug Brinsupri and deeming the recent stock pullback excessive. HC Wainwright also maintained a positive outlook—setting a $230 target and forecasting 2026 revenues above $1 billion based on early Brinsupri sales and the value of Insmed’s pipeline—signaling continued favorable re-rating from Wall Street.

Insmed is a global biotech company specializing in treatments for rare and severe respiratory diseases. Its portfolio includes Arikayce, for nontuberculous mycobacterial lung disease, and Brinsupri, for bronchiectasis. Approved in 2025 in both the U.S. and Europe, Brinsupri is the first targeted therapy for non–cystic fibrosis bronchiectasis and is viewed as Insmed’s next-generation growth driver.